Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Celldex Therapeutics, Inc. - Common Stock (NQ:CLDX)

20.89 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Celldex Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Why Bluegreen Vacations Shares Are Trading Higher By Around 105%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares jumped 396.2% to $145.49 after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge... 
Via Benzinga
Celldex Therapeutics Inc. (NASDAQ: CLDX) Highlighted for Surprising Price Action
Via Investor Brand Network
Why Is Inflammation Disease-Focused Celldex Therapeutics Stock Trading Higher Today?
Celldex Therapeutics Inc (NASDAQ: CLDX) released topline results from its Phase 2 trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria (CSU) refractory to... 
Via Benzinga
4 Analysts Have This to Say About Celldex Therapeutics
 
Via Benzinga
Celldex Therapeutics: Q1 Earnings Insights
 
Via Benzinga
Why Celldex Therapeutics Shares Are Trading Higher Today
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Prurigo Nodularis at 12th World Congress on Itch (WCI) 2023
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics to Present at Cantor Global Healthcare Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Wall Street's Top 10 Stock Calls This Week - Sunday, Aug. 27
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2023
 
Via Benzinga
Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Announces Upcoming Barzolvolimab Presentations at EAACI 2023
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics to Present at Jefferies Healthcare Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Announces First Patient Dosed in Phase 1 Study of CDX-585 in Patients with Advanced Malignancies
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622 at IMMUNOLOGY2023™
From Celldex Therapeutics, Inc.
Via GlobeNewswire
A New Era In Regenerative Medicine? BioRestorative Therapies (NASDAQ: BRT) Reports Leading The Expansion Of The Adipose-Derived Stem Cell Therapy Market
Brown Adipose-Derived Stem Cell (BADSC) therapy has emerged as a groundbreaking innovation in regenerative medicine, capturing the attention of scientists, clinicians and investors alike. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Celldex Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics to Present at H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Union Pacific, Kosmos Energy, Fisker And Other Big Stocks Moving Higher On Monday
U.S. stocks traded higher, with the Dow Jones gaining more than 300 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at AAAAI 2023
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
From Celldex Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.